A Phase 2A Dose-ranging and Pharmacokinetic Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism

NCT01653379 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

42

Enrollment

INDUSTRY

Sponsor class

Conditions

Secondary Hyperparathyroidism

Interventions

DRUG: DP001

Sponsor

Deltanoid Pharmaceuticals